Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome

• Published in: World journal of critical care medicine Vol. 6; no. 1; pp. 74 - 78
• Main Authors: Albert, Martin, Corsilli, Daniel, Williamson, David R, Brosseau, Marc, Bellemare, Patrick, Delisle, Stéphane, Nguyen, Anne Qn, Varin, France
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 04.02.2017
• Subjects: Prospective Study; Acute respiratory distress syndrome; Inhaled milrinone; Prostacyclin; Hypoxemia; Nitric oxide; Pulmonary hypertension
• ISSN: 2220-3141; 2220-3141
• DOI: 10.5492/wjccm.v6.i1.74

To evaluate the safety and efficacy of inhaled milrinone in acute respiratory distress syndrome (ARDS). Open-label prospective cross-over pilot study where fifteen adult patients with hypoxemic failure meeting standard ARDS criteria and monitored with a pulmonary artery catheter were recruited in an academic 24-bed medico-surgical intensive care unit. Random sequential administration of iNO (20 ppm) or nebulized epoprostenol (10 μg/mL) was done in all patients. Thereafter, inhaled milrinone (1 mg/mL) alone followed by inhaled milrinone in association with inhaled nitric oxide (iNO) was administered. A jet nebulization device synchronized with the mechanical ventilation was use to administrate the epoprostenol and the milrinone. Hemodynamic measurements and partial pressure of arterial oxygen (PaO ) were recorded before and after each inhaled therapy administration. The majority of ARDS were of pulmonary cause ( = 13) and pneumonia ( = 7) was the leading underlying initial disease. Other pulmonary causes of ARDS were: Post cardiopulmonary bypass ( = 2), smoke inhalation injury ( = 1), thoracic trauma and pulmonary contusions ( = 2) and aspiration ( = 1). Two patients had an extra pulmonary cause of ARDS: A polytrauma patient and an intra-abdominal abscess Inhaled nitric oxide, epoprostenol, inhaled milrinone and the combination of inhaled milrinone and iNO had no impact on systemic hemodynamics. No significant adverse events related to study medications were observed. The median increase of PaO from baseline was 8.8 mmHg [interquartile range (IQR) = 16.3], 6.0 mmHg (IQR = 18.4), 6 mmHg (IQR = 15.8) and 9.2 mmHg (IQR = 20.2) respectively with iNO, epoprostenol, inhaled milrinone, and iNO added to milrinone. Only iNO and the combination of inhaled milrinone and iNO had a statistically significant effect on PaO . When comparing the effects of inhaled NO, milrinone and epoprostenol, only NO significantly improved oxygenation. Inhaled milrinone appeared safe but failed to improve oxygenation in ARDS.